|
 |
 |
Shareholder Services |
 |
 |
 |
 |
 |
For Investors
The information on this site is intended only for investors. All visitors should read the important advisory information by clicking here. |
 |
 |
 |
 |
 |
< Back |
 |
 |
 |
Current shareholders of record can obtain information about
Schering-Plough stock through the Bank of New York Stock
Transfer Web site at www.stockbny.com. As
Schering-Plough's registrar and transfer and dividend
disbursing agent, The Bank of New York provides
information on:
How to enroll in the reinvestment plan
How to obtain duplicate statements
How to withdraw, sell or transfer shares
The site also offers up-to-the-minute stock quotes, a
glossary of terms and frequently asked questions.
Shareholders can also check account balances, market
valuation, and transaction history, request information, and
receive transfer instructions by forwarding e-mail requests to
shareownersvcs@bankofny.com, or by contacting The Bank
of New York at the following address or telephone number:
The Bank of New York
Shareholder Relations Department
P.O. Box 11258
Church Street Station
New York, NY 10286-1258
Telephone: Toll free (877) 429-1240 or (610) 382-7833 for
calls outside the U.S.
Address change requests should be directed to:
The Bank of New York
Receive and Deliver Department
P.O. Box 11002
Church Street Station
New York, NY 10286-1002
Links: |
 |
 |
 |
|
 |
 |
 |
Annual Reports
Systematic Investment Program |
 |
 |
|
 |
 |
 |
 |
 |
 |
| |
World Headquarters:
2000 Galloping Hill Road, Kenilworth, N.J. 07033-0530 |
 |
| |
Chairman and CEO:
Fred Hassan |
 |
| |
Number of employees:
55,000 |
 |
 |
| |
Net sales (2007):
$12.7 billion |
 |
 |
| |
Business operations in more than:
140 countries |
 |
| |
Largest-selling products:
VYTORIN*, ZETIA*, REMICADE, NASONEX. |
 |
| |
R&D investment
(2007):
$2.9 billion |
 |
| |
Areas of research:
cardiovascular disease, central nervous system disorders, immunology and infectious disease, oncology, respiratory diseases and women's health
*VYTORIN and ZETIA are managed through a joint venture with Merck & Co., Inc. Schering-Plough accounts for the joint venture under the Equity method. Total cholesterol joint venture sales were $5.2 billion in 2007.
|
 |
|
 |
 |
 |
|